Eschscholzia californica Cham. (Papaveraceae) is traditionally used by the Indians as a medicinal plant for its anxiolytic, anticonflict, analgesic and sedative properties. The mechanisms of action for the sedative and anxiolytic activities have not been clearly established and so to further investigate the pharmacological profile of E. californica in some painful conditions, a 70% v/v ethanol extract, DER native =5:1, was tested in rat models of neuropathy induced by chronic constriction injury of the sciatic nerve (CCI), with chemotherapeutic oxaliplatin, and osteoarthritis caused by intrarticular injection of monoiodoacetate. In the CCI model evaluated in the rat paw-pressure test, the examined extract (100 mg kg -1 p.o.) showed an antihyperalgesic effect. Eschscholzia extract, after single injection at a dose of 100-300 mg kg -1 p.o., produced also a statistically significant decrease of pain perception on hyperalgesia induced by oxaliplatin and osteoarthritis, while in the same condition gabapentin did not display any antihyperalgesic effect. Furthermore, in the range of antihyperalgesic doses, the extract was efficacious in the hot-plate (thermal stimulus) and carrageenan tests (inflammatory model) without producing any behavioral impairment, as evaluated by the Irwin test. The analgesic effect exhibited by Eschscholzia extract in the mouse hot-plate test was not antagonized by naloxone, indicating that opioid neurotransmission is not involved in the effect.
Eschscholzia californica Cham. (California poppy, Papaveraceae) is an annual plant found throughout California and traditionally used by the Indians as a medicinal plant for its anxiolytic, anticonflict, analgesic and sedative properties [1] . The mechanisms of action for the sedative and anxiolytic activities have not been clearly established, although the involvement of several receptors have been observed and recently it has been reported that a 70% (v/v) ethanol extract of California poppy was able to bind to 5-HT(1A) and 5-HT(7) receptors at 100 μg/mL [2] . To further investigate the pharmacological profile of E. californica in some painful conditions, a 70% v/v ethanol extract, DER native =5:1, was used for the tests in rat models of neuropathy induced by chronic constriction injury of the sciatic nerve (CCI), repeated treatment with the chemotherapeutic agent oxaliplatin, and osteoarthritis caused by intrarticular injection of monoiodioacetate and inflammation caused by carrageenan plantar injection.
In the CCI model evaluated in the rat paw-pressure test, the examined extract (100 mg kg -1 p.o.) showed an antihyperalgesic activity ( Figure 1 ). The anti-hyperalgesic effect induced by 300 mg kg -1 did not differ from that obtained with a dose three folds lower (data not shown extract, after single injection at a dose of 100 mg kg -1 and 300 mg kg -1 p.o., respectively, produced also a statistically significant decrease of pain perception on hyperalgesia induced by oxaliplatin and osteoarthritis, while in the same condition gabapentin did not display any antihyperalgesic effect ( Figure 1 ). Particularly, the extract peaked 30 min after administration ( Figure 1 ). Similarly, in the painful condition caused by intraplantar injection of carrageenan, California poppy extract reduced hyperalgesia at the dose of 300 mg kg -1 p.o., 30 min after administration ( Figure 1 ). Furthermore, in the same range of doses, the extract was efficacious in the mouse hot-plate test in the presence of a thermal stimulus. The analgesic effect exhibited by California poppy extract in the mouse hot-plate test was of an intensity comparable to that exhibited by gabapentin and it was not antagonized by naloxone (1 mg kg -1 i.p.) indicating that opioid neurotransmission is not involved in the effect ( Table 1) .
The examined extract, at the dose which was effective in relieving acute and persistent pain, was tested in order to assess its effect on mouse behaviour. At the highest dose employed, the extract did not induce any alteration of either mouse gross behaviour or show any other side effect, as observed in the Irwin test (data not shown). Moreover, mice treated with California poppy extract were evaluated for motor coordination by using the rota-rod test. The endurance time, evaluated before and 15, 30 and 45 minutes after the beginning of the rota-rod test showed the lack of any impairment in the motor coordination of the treated mice ( Figure 2 ). The above reported results suggest that the freezedried extract (DER native =5:1) of E. californica might represent a promising material for the therapy of acute and chronic pain.
Experimental
Plant material: Eschscholzia californica (California poppy) was cultivated at Aboca's Organic Farms in 2007 (Aboca, San Sepolcro (AR), Italy). After harvest, the drying process was carried out using special equipment, air-heated ovens, with cells in which forced air is circulated at a temperature and level of humidity that are carefully controlled (the temperature is kept between 32° and 40°C). After this, the desired plant material was separated from any extraneous bodies present (weeds, insects, seeds) based on specific weight, using aero-separators and densimeters, and cut, to reduce the herb to the proper dimensions according to its intended use (for herbal tea, extraction, micronized powder).
Preparation of plant extract:
Eschscholzia californica freeze-dried extract was produced by Aboca Spa (Sansepolcro, AR) and was obtained according to the extraction procedure described below. The dried ground tops were extracted by percolation with a hydro ethanolic solution (70% v/v) and herb/solvent ratio of 1:10.
After 8-10 h, the plant extract was filtered to remove the exhausted herb and concentrated under vacuum to remove the ethanol. The extract was freeze-dried under vacuum, without the use of either heat or excipients, at temperatures less than -50°C. The Drug Extract Ratio (DER) was 5:1 and the batch number was n. 7B1150. The content of protopin in this batch was 0.22%, analyzed by a HPLC method. Chromatograms were recorded between 200 and 450 nm. DAD spectra were stored for all peaks exceeding a threshold of 0.1 mAu and detection was performed at 280 nm.
Calibration curves:
A calibration curve was obtained from an 80% MeOH solution (containing 4% of diluted HCl) of protopin in the range between 0.025 and 0.00625 mg/mL.
Pharmacological assays:
Drugs were either dissolved in isotonic (NaCl 0.9%) saline solution or dispersed in 1% carboxymethylcellulose sodium salt (CMC, Fluka Chemie GmbH, Steinheim, Germany) immediately before use. Drug concentrations were prepared so that the necessary dose could be administered in a volume of 10 mL kg -1 by i.p. and p.o. injection. 
Animals: Male

Chronic constriction injury:
A peripheral mono neuropathy was produced in adult rats by placing loosely constrictive ligatures around the common sciatic nerve, according to the method described by Bennet and Xie [3] .
Monoiodoacetate injection: Joint damage was induced by a single intra-articular injection of 2 mg of sodium monoiodoacetate into the left knee joint of anaesthetized rats in a total volume of 25 μL. The dose of iodoacetate was chosen based on previous literature [4] and in-house dose response data using 0.5, 1 and 2 mg.
Oxaliplatin injection:
Hyperalgesia was induced by 15 injections for 5 consecutive days every week for 3 weeks of Oxaliplatin, 2.4 mg kg -1 (15 i.p. injections-cumulative dose 36 mg kg -1 ) [5] .
Paw-pressure test:
The instrument exerts a force which is applied at a constant rate (32 g per second) with a cone-shaped pusher on the upper surface of the rat hind paw. The force is continuously monitored by a pointer moving along a linear scale. The pain threshold is given by the force that induces the first struggling from the rat. Pretested rats which scored below 40 g or over 80 g during the test before drug administration (25%) were rejected. An arbitrary cut off value of 250 g was adopted.
Hot plate test: Mice were placed inside a stainless steel container, which was set thermostatically at 52.5±0.1°C in a precision waterbath from KW Mechanical Workshop, Siena, Italy. Reaction times (s) were measured with a stopwatch before and 15, 30, 45 and 60 min after administration of the drug. The endpoint used was the licking of either the forepaws or hind paws. Those mice scoring less than 12 and more than 18 s in the pretest were rejected (30%). An arbitrary cutoff time of 45 s was adopted.
Carrageenan test: Rat paw volumes were measured using a plethysmometer (Ugo Basile, Varese, Italy). Rats received the investigated extract 30 min after a 0.1mL injection of 1.0% carrageenan in the right hind paw. Four h after the injection of carrageenan, the pain threshold of the right hind paw was measured and compared with saline/carrageenan-treated controls.
Statistical analysis:
All experimental results are given as the mean ± S.E.M. An analysis of variance (ANOVA), followed by Fisher's Protected Least Significant Difference procedure for post-hoc comparison, were used to verify significance between two means. Data were analyzed with the StatView software for the Macintosh. P values of less than 0.05 were considered significant.
